20101 results for «»

Filter By

20101 results

Focus on the right ventricle: patient selection and clinical outcomes after tricuspid valve intervention

16 Nov 2025 – From PCR London Valves 2025

Focused on the often-overlooked right ventricle, this session elucidates methods for accurate assessment of right ventricular function prior to transcatheter tricuspid valve interventions. It explores the role of right heart catheterisation in patient selection and timing, and evaluates long-term remodeling patterns post-procedure, providing critical insights for...

Focus on the right ventricle: patient selection and clinical outcomes after tricuspid valve intervention

Rapid fire on ortothopic TTVR

16 Nov 2025 – From PCR London Valves 2025

This rapid-fire session presents an overview of the latest orthotopic transcatheter tricuspid valve replacement (TTVR) devices. It features concise discussions on multiple innovative systems including Evoque, Laplace, VDyne, Topaz, and Cardiovalve, offering insights into their design characteristics and clinical applications in tricuspid valve disease management.

Hotline - TAVI - Part 1

16 Nov 2025 – From PCR London Valves 2025

This comprehensive session examines the latest evidence and clinical trial data on TAVI, including comparisons of balloon-expandable versus self-expanding valves in failed bioprostheses, techniques to reduce coronary obstruction risk, and real-world outcomes across diverse populations. Cost-effectiveness analyses and longitudinal studies further inform best practices for optimizing...

Featured research - Tricuspid valve interventions - Part 2

16 Nov 2025 – From PCR London Valves 2025

This session highlights recent advances in tricuspid valve interventions with a focus on complex clinical scenarios. Topics include percutaneous annuloplasty as a bridge to edge-to-edge repair, long-term outcomes from the TriCLASP study, novel stratification methods to guide intervention, liver stiffness prognostics, right atrial remodeling post-repair, and...

Valve interventions in congenital heart disease

16 Nov 2025 – From PCR London Valves 2025

This session presents complex valve interventions in congenital heart disease, highlighting challenging cases such as positional hypoxaemia due to iatrogenic atrial defects, navigating residual shunts after PFO closure, and transcatheter pulmonary valve replacement in native right ventricular outflow tracts without pre-stenting. It also examines an intriguing...

Challenging TAVI

16 Nov 2025 – From PCR London Valves 2025

This session addresses the complexities encountered in transcatheter aortic valve implantation (TAVI) in challenging anatomical settings. It reviews management of bicuspid valves with calcification, horizontal aorta, coronary artery anomalies, and navigation of difficult angles. Case studies illustrate techniques to optimize commissural alignment and strategies to address...

Breakout session on Simul-Imaging

16 Nov 2025 – From PCR London Valves 2025

This session focuses on the evolution and impact of simul-imaging in interventional cardiology. It reviews historical perspectives on the FIM procedure, the role of simulation in accelerating the learning curve, and innovative approaches to simulation-based training. Additionally, the session highlights cutting-edge imaging innovations from major industry...

TAVI: unusual complications

16 Nov 2025 – From PCR London Valves 2025

This session examines rare and unusual complications arising from TAVI procedures. Topics include early recognition and management of frozen leaflets, ventricular septal perforation post-valve-in-valve TAVI, acute leaflet dysfunction, aorto-ventricular fistula formation, and percutaneous closure techniques for fistulas involving the right coronary sinus and right ventricle, emphasizing...

Nightmare mitral interventions

16 Nov 2025 – From PCR London Valves 2025

This session presents complex mitral valve intervention cases highlighting procedural challenges and innovative solutions. It includes management of embolised transcatheter mitral valve replacements (TMVR), bailout redo transcatheter edge-to-edge repair (TEER), complications such as acute hypoxia and atrial wall perforations, and the application of TAVI skills in...

TAVI and coronary artery disease

16 Nov 2025 – From PCR London Valves 2025

This session focuses on the interplay between TAVI and coronary artery disease, discussing high-risk TAVR cases requiring complex left main PCI with prophylactic ECMO support. It provides guidance on timing and strategies for managing concomitant coronary artery disease in TAVI patients, addressing the critical decision-making process...

What are the key considerations when managing combined mitral and tricuspid regurgitation?

17 Feb 2026 – From PCR London Valves 2025

Fabien Praz and Neil Fam talk about the management of patients with combined mitral and tricuspid regurgitation, who are often elderly with heart failure and multiple comorbidities. Careful assessment—including echocardiography, hemodynamics, and sometimes CT—is crucial to identify the dominant lesion. Surgery is preferred if feasible, but...

What are the key considerations when managing combined mitral and tricuspid regurgitation?

One-year results from the ADALA trial

16 Nov 2025 – From PCR London Valves 2025

Left atrial appendage (LAA) closure is a new focus at this year’s PCR London Valves Course, and, in this interview, Xavier Freixa and Christopher Allen discuss the ADALA trial and its impact on post-occlusion management.

The study compared three months of low-dose DOAC with three months of...

One-year results from the ADALA tria

Is iatrogenic atrial septum defect closure a necessary procedure?

17 Nov 2025 – From PCR London Valves 2025

Philipp Lurz and Saibal Kar discuss iatrogenic atrial septal defects from transseptal procedures. Small ones usually close on their own, while large defects causing significant shunting need closure to prevent right heart overload. Some moderate defects may be beneficial by decompressing the left atrium, so closure...

Is iatrogenic atrial septum defect closure a necessary procedure?

PARTNER 3 — 7-year follow-up: what it means for low-risk patients

16 Nov 2025 – From PCR London Valves 2025

Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.

They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...

PARTNER 3 — 7-year follow-up: what it means for low-risk patients

Should we consider TTVR in patients with straightforward anatomy who are eligible for T-TEER?

17 Nov 2025 – From PCR London Valves 2025

Lukas Stolz and Rebecca Hahn discuss advances in transcatheter tricuspid valve intervention, emphasising that reducing tricuspid regurgitation (TR) to mild levels is key for improving patient outcomes, including mortality and heart failure hospitalisations. Decision-making between transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) depends...

Should we consider TTVR in patients with straightforward anatomy who are eligible for T-TEER?

TAVI: vascular complications

16 Nov 2025 – From PCR London Valves 2025

This session examines vascular complications associated with transfemoral TAVI procedures, featuring challenging cases such as initial procedural obstacles, complex post-TAVI vascular events, and unusual complications. It also explores advanced techniques like intravascular lithotripsy to optimize TAVI outcomes in patients with severe calcific iliofemoral disease.

TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation

16 Nov 2025 – From PCR London Valves 2025

Georg Nickenig and Christopher Allen discuss transcatheter replacement for the tricuspid valve and a dedicated transfemoral device in this interview, focusing on the TARGET study.

TARGET set out to answer two questions: can tricuspid regurgitation (TR) be reduced to mild or zero, and what are the safety...

TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation

TAVI for aortic regurgitation in high surgical risk: outcomes in 700 patients from ALIGN-AR

12 Feb 2026 – From PCR London Valves 2025

Christopher Allen and Raj Makkar sit down to review the ALIGN-AR trial and its implications for treating native aortic regurgitation. 

ALIGN-AR was a pivotal, single-arm, multicenter investigational study designed to evaluate a dedicated transcatheter solution in patients with moderate-to-severe native AR who were considered high risk for...

Outcomes in 700 patients from ALIGN-AR regarding TAVI for AR in high surgical risk

The D-PACE scoring system Prediction of high-grade conduction disturbances after TAVI

16 Nov 2025 – From PCR London Valves 2025

Michael Joner and Francesco Saia discuss the newly developed D-PACE Score, a tool designed to predict delayed AV block occurring more than 24 hours after TAVI—an unmet clinical need given that current risk models focus mainly on early events. The next steps aim to refine the...

The D-PACE scoring system - Can we predict high-grade conduction disturbances after TAVI?

Why is TAVI a different procedure in patient with pure aortic regurgitation?

15 Nov 2025 – From PCR London Valves 2025

In this video, Juan Granada, Michael Borger and Joao Cavalcante highlight that aortic insufficiency differs from aortic stenosis and is often underestimated. Early, comprehensive evaluation and imaging are crucial. Surgery is standard for severe cases, while TAVI with dedicated devices is an option for high-risk patients.

This...

Why is TAVI a different procedure in patient with pure aortic regurgitation?
Didn’t find what you were looking for?